KDM1A and cancer: In cancer, LSD1 suppresses interferon signaling, antigen presentation, and immune-stimulatory endogenous retroviral elements, whereas its inhibition reactivates type I interferon pathways, enhances T cell infiltration, and sensitizes tumors to immune checkpoint blockade (ICB) [7].